Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The interferons.

L M Itri1

  • 1R. W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey 08869.

Cancer
|August 15, 1992
PubMed
Summary
This summary is machine-generated.

Interferons (IFN) show efficacy as single agents but hold greater potential in combination therapies. Further research into IFN mechanisms and interactions is needed for optimal combination regimens.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Cancer-related anaemia requires higher doses of epoetin alfa than chronic renal failure replacement therapy.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2001
Same author

Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition.

The oncologist·2000
Same author

Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury.

Proceedings of the National Academy of Sciences of the United States of America·2000
Same author

Optimal hemoglobin levels for cancer patients.

Seminars in oncology·2000
Same author

Chemotherapy-induced anemia in adults: incidence and treatment.

Journal of the National Cancer Institute·1999

Area of Science:

  • Immunology
  • Oncology
  • Virology

Background:

  • Interferons (IFN) have been in clinical trials for a decade, with significant understanding gained regarding their use as single agents.
  • Alpha-IFN (IFN-α) is the most studied subtype, demonstrating antitumor and antiviral properties.
  • IFN-α is FDA-approved for hairy cell leukemia, AIDS-related Kaposi sarcoma, and condylomata acuminata.

Purpose of the Study:

  • To review the established efficacy of interferons (IFN) as single agents.
  • To explore the potential of combination therapies involving IFN.
  • To highlight the need for improved preclinical models for combination therapy design.

Main Methods:

  • Review of clinical trial data and established uses of interferons.
  • Analysis of combination therapy trials, including IFN-α with 5-fluorouracil and zidovudine.

Related Experiment Videos

  • Discussion of the need for enhanced preclinical models.

    • Main Results:

    • Single-agent IFN therapy has demonstrated efficacy in specific clinical contexts.
    • Combination therapies, such as IFN-α with 5-fluorouracil or zidovudine, show significant therapeutic impact.
    • Current data suggest that the greatest therapeutic potential of IFN lies in combination regimens.

    Conclusions:

    • While effective alone, interferons (IFN) show promise in combination with other therapeutic agents.
    • Optimizing combination regimens requires a deeper understanding of IFN mechanisms and biochemical interactions.
    • Further development of preclinical models is crucial for advancing combination therapy strategies.